/
CRSP
$55.12-$1.23 (-2.19%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.4B
98M shares
52-week range
$44.12 – $78.48
32% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.43%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-101.52
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $289.6M | $719.0K | $913.1M | $436.0K | $370.0M | $35.0M | $3.5M |
| Cost of revenue | $113.8M | $179.4M | $269.4M | $101.2M | $110.3M | $130.3M | $110.3M | $233.0M |
| Gross profit | −$110.6M | $110.2M | −$268.7M | $811.9M | −$109.8M | $239.8M | −$75.3M | −$229.4M |
| Gross margin | -3541.9% | 38.1% | -37369.7% | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| R&D | $113.8M | $179.4M | $221.4M | $340.6M | $461.6M | $387.3M | $320.7M | $265.3M |
| Operating income | −$158.9M | $46.7M | −$354.4M | $373.5M | −$673.2M | −$222.5M | −$466.6M | −$568.3M |
| EBITDA | −$155.4M | $51.5M | −$345.3M | $397.5M | −$626.3M | −$130.9M | −$343.4M | −$558.5M |
| Net income | −$165.0M | $66.9M | −$348.9M | $377.7M | −$650.2M | −$153.6M | −$366.3M | −$581.6M |
| Net margin | -5281.1% | 23.1% | -48520.9% | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| EPS (diluted) | -3.44 | 1.17 | -5.29 | 4.70 | -8.36 | -1.94 | -4.34 | -6.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $36M | $-4.83 | $-5.81–$-4.02 | 17 |
| 2027 | $131M | $-3.70 | $-5.08–$-1.56 | 16 |
| 2028 | $537M | $-2.57 | $-9.86–$10.40 | 9 |
| 2029 | $2.2B | $2.90 | $-0.79–$13.30 | 3 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
www.crisprtx.com- Employees
- 393
- IPO / List date
- Oct 19, 2016
- HQ
- ZUG
Held by traders on TradeandTell
No one on the platform currently holds CRSP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CRSP as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CRSP yet.
